Why CPSR is Legally Required for Cosmetics in Switzerland
Legal background
Swiss cosmetic legislation requires manufacturers to ensure that their products are safe before making them available to consumers. To fulfil this obligation, every cosmetic formula must undergo a comprehensive safety assessment, this obligation is established under the Swiss Ordinance on Cosmetic Products (SR 817.023.31), which mirrors the framework of the EU Cosmetics Regulation (EC) No 1223/2009, the results of which are documented in the CPSR.
Failing to obtain a compliant CPSR can result in:
- Product withdrawal or recall due to insufficient safety documentation
- In-market control failures by Swiss authorities
- Increased regulatory scrutiny for current and future products
- Reputational damage linked to safety concerns or consumer complaints
CPSR Assistance for Cosmetic Swiss Compliance from Obelis
As your trusted regulatory partner, Obelis Group ensures that your Cosmetic Product Safety Report fully complies with Swiss requirements by guiding you through each step of the safety assessment process. We support you by gathering and reviewing all necessary product data (such as formula composition, raw material specifications, laboratory test results, impurity profiles, and toxicological information) and preparing them for evaluation by a qualified safety assessor. We identify missing elements, verify ingredient compliance according to Swiss restrictions, and ensure all safety considerations align with current scientific standards. Once the assessment is complete, we confirm that the CPSR is properly integrated into the PIF and reflects the product’s actual market presentation. With our expertise, you receive a complete, reliable safety report tailored to Swiss legislation, enabling you to place your cosmetic products on the market confidently and responsibly.
FAQs About CPSR in Switzerland
Yes. Under Swiss legislation every cosmetic product must undergo a formal safety assessment before being placed on the Swiss market. The CPSR documents this assessment and forms a critical part of the Product Information File (PIF) required for compliance in Switzerland.
A CPSR must be prepared and signed by a qualified safety assessor, typically a professional with expertise in toxicology, dermatology, pharmacology, or cosmetic science. They evaluate the formula, toxicological profiles of each ingredient, product exposure, and supporting laboratory data to confirm the product is safe for its intended use.
To complete a CPSR, manufacturers must provide detailed formula composition, raw material specifications, purity and contaminant profiles, results from required laboratory tests (such as stability, microbiology, and challenge testing), packaging information, and any relevant toxicological data. This ensures the assessor can evaluate safety under normal or foreseeable usage conditions.
Often yes, provided the CPSR is complete, scientifically sound, and reflects the product exactly as marketed in Switzerland. Although Swiss law is closely aligned with EU cosmetic safety principles, the report may still require adaptations, such as updates to ingredient restrictions, additional test results, or modifications to reflect Swiss market specifics.
Yes. Any change to the formula, raw material suppliers, packaging, intended use, or product claims may affect the safety assessment and require the CPSR to be reviewed and updated accordingly. Even minor reformulations can alter the toxicological profile or exposure levels assessed in the original report. Obelis reviews your existing CPSR against any planned changes and advises on whether a full reassessment or a targeted update is required to maintain Swiss compliance.
In principle, each cosmetic product requires its own CPSR, as the safety assessment must reflect the specific formula, intended use, and exposure profile of that individual product. However, in some cases a single CPSR may cover a product range if the formulas are sufficiently similar and the safety assessor determines that a grouped assessment is scientifically justified. Obelis advises on whether a grouped approach is viable for your product portfolio and ensures any consolidated report meets Swiss regulatory expectations.
